CYP1B1 Genotype (Leu432Val, Asn453Ser)

Your body breaks down estrogen and certain environmental chemicals using a small set of specialized enzymes. The CYP1B1 enzyme is one of them, and two inherited variants in its gene, Leu432Val and Asn453Ser, can subtly change how that processing works. This test reads your DNA at those two spots so you can see which version you carry.

This is a research-grade genetic marker rather than a settled clinical test. The associations between these variants and conditions like lung cancer, prostate cancer, and hypertension are real in some studies but inconsistent across populations, so a result here is best treated as one data point in a larger picture, not a diagnosis.

What These Variants Actually Do

CYP1B1 (cytochrome P450 1B1) is a phase I detox enzyme, meaning it performs the first chemical step your body uses to modify and clear estrogen, polycyclic aromatic hydrocarbons (a family of chemicals found in tobacco smoke, grilled meats, and air pollution), and other compounds. It is made in many tissues, including the breast, prostate, lung, and reproductive organs.

The Leu432Val variant (also called rs1056836) swaps one building block in the enzyme for another at position 432. Laboratory studies suggest the Val version has altered activity rather than uniformly higher activity, with a particular preference for producing 4-hydroxyestradiol (a more reactive form of estrogen). Some studies have also found lower CYP1B1 messenger RNA levels in Val/Val carriers, so the net effect depends on the substrate and tissue. The Asn453Ser variant (rs1800440) swaps a different building block at position 453, and is linked to lower amounts of the enzyme because the protein is broken down more quickly inside the cell.

Faster, slower, or shifted processing is not automatically good or bad. CYP1B1 produces 4-hydroxyestradiol, a form of estrogen that can generate cell-damaging byproducts called free radicals if not cleared by downstream enzymes. So genotype effects depend on the rest of your detox system, your hormone levels, and your exposures.

Lung Cancer Risk

The most replicated cancer association is with lung cancer. Pooled analyses of thousands of people found that carrying the Val variant at position 432 was linked to roughly 22 to 41 percent higher lung cancer risk depending on the genetic model, with the strongest signal in homozygous Val/Val carriers. The link was more pronounced in Caucasians and in smokers.

A separate meta-analysis reported the overall increase in lung cancer risk for Val/Val carriers compared to Leu/Leu at about 1.43-fold. This is a modest, low-penetrance effect, meaning the variant alone does not cause lung cancer. It nudges the underlying risk upward and appears to interact meaningfully with smoking.

For Asn453Ser, the overall lung cancer association was not significant in the same analyses. If you carry the Val/Val genotype and you smoke or have heavy secondhand exposure, this is one more reason to take that exposure seriously.

Prostate Cancer

Prostate cancer evidence is genuinely mixed. One large meta-analysis found no significant Leu432Val association in the overall population. In Asian subgroups, however, the same analysis found a Val allele linked to roughly 1.5 times higher risk in dominant models and over 2 times higher in recessive models.

For Asn453Ser, a modest signal emerged in the overall population, with the Ser-carrying genotypes linked to about 18 percent higher prostate cancer risk in a dominant model. These effects are small and population-dependent, not a basis for changing standard prostate cancer screening decisions on their own.

Endometrial Cancer

For endometrial cancer the pattern flips between the two variants. Carrying at least one Val allele at position 432 was associated with about 19 percent higher endometrial cancer risk in pooled analysis, though one earlier meta-analysis found no significant association, so the evidence is not entirely uniform. Carrying the Ser allele at position 453, by contrast, was associated with about 18 percent lower endometrial cancer risk, with heterozygous Ser/Asn carriers showing a similar decrease.

This is a useful illustration that the two variants do different things and can point in opposite directions for the same disease. They are not interchangeable.

Why Opposite Findings Can Both Be Real

It can be confusing that one variant looks risky for lung cancer but neutral or protective elsewhere, and that the same variant can show no overall effect but a real subgroup signal. The explanation is that CYP1B1 sits at a crossroads. Its products can be harmful or beneficial depending on which estrogens are circulating, what carcinogens you are exposed to, and how quickly your downstream enzymes clean up reactive byproducts. So the same enzyme tweak can shift risk in different directions for different tissues, exposures, and populations.

This is why a CYP1B1 result is best read as a phenotype indicator rather than a simple good number or bad number. It tells you something about how your detox system is wired, not a single fixed risk score.

Breast and Colorectal Cancer

Despite intense interest, neither Leu432Val nor Asn453Ser shows a consistent overall association with breast or colorectal cancer in large meta-analyses. For breast cancer, pooled odds ratios for Asn453Ser were 0.96 in heterozygotes and 0.98 in homozygous Ser carriers, both close to no effect. The same large pooled analysis concluded Asn453Ser is not associated with breast cancer risk overall.

A separate colorectal cancer meta-analysis found no significant association for either variant. If your reason for testing is breast or colon cancer concern, this result is not where you should put most of your attention.

Hypertension and Other Phenotypes

Outside cancer, the Leu432Val variant has been linked to hypertension in midlife Slovak women. Carriers of at least one Val allele had roughly 1.82 times the odds of hypertension compared to Leu/Leu women. Asn453Ser was not associated with hypertension in the same study population.

In the same population, the Leu/Leu genotype at position 432 was associated with higher risk of menopausal vasomotor, urogenital, and psychological symptoms, while the Asn/Asn genotype at position 453 appeared protective against psychological symptoms. These are population-specific findings and have not been broadly replicated.

Treatment Response Signals

A small clinical study in castration-resistant prostate cancer found that men with the 432 Val/Val genotype had significantly lower response rates to docetaxel chemotherapy, shorter progression-free survival, and shorter overall survival. A separate study in advanced non-small cell lung cancer treated with docetaxel reported overall survival of 3.63 months in Val/Val carriers versus 9.83 months in others.

In triple-negative breast cancer treated with TAC chemotherapy, the 432 GG (Val/Val) genotype was associated with disease-free survival of 37 percent versus 71 percent in other genotypes, with an adjusted relapse risk roughly 4.18 times higher. These are small studies that need confirmation, but they hint at a future role for the marker in chemotherapy planning.

One-Time Result

This is a fixed germline genotype. Your two letters at each variant do not change over your lifetime, and you do not need to repeat the test. The value of the result comes from how you and your clinicians use it across years of decisions, not from retesting the marker.

What does benefit from ongoing tracking is the downstream picture: regular lung cancer screening if you smoke or have smoked, prostate-specific antigen and prostate exams on the schedule your clinician recommends, blood pressure measurements, and gynecologic surveillance appropriate to your age. These companion checks are where a CYP1B1 result becomes actionable, not by retesting the gene.

What an Unexpected Result Should Trigger

If your genotype includes the Val allele at position 432, particularly Val/Val, the most useful next steps are exposure-focused. That means an honest review of your tobacco use, including secondhand smoke and historical exposure, and following recommended lung screening for your age and history. If you have a strong family history of prostate cancer, the prostate cancer subgroup data can inform an earlier conversation with a urologist about PSA tracking.

If you are a woman with menopausal symptoms or hypertension and your result includes risk variants from the Slovak studies, this is a reasonable prompt for a more detailed cardiovascular and hormonal workup with your clinician. Because the underlying associations are modest and population-specific, this result by itself does not warrant aggressive intervention. It earns its keep by adding context to clinical decisions that would already be on the table.

For any genotype result that surprises you or seems significant to your family history, the right specialist to involve is a genetic counselor or a clinician familiar with pharmacogenomics. They can integrate your variant with ancestry, current medications, and personal cancer history.

When Results Can Be Misleading

This test only reports the two variants it is designed to detect. A typical result here does not rule out other rare variants in CYP1B1 or related genes that could affect estrogen and carcinogen metabolism. If you are worried about a specific inherited condition, broader sequencing through a clinical lab may give a more complete answer.

A variant of uncertain significance (VUS) call, where the lab cannot say whether a detected change is benign or disease-related, is uncommon for these two well-studied positions but can appear in adjacent variants if your assay reports them. Treat such calls as a prompt for follow-up rather than a diagnosis.

Allele frequencies and disease associations vary by ancestry. Several of the strongest CYP1B1 effects appear only in specific populations, such as the prostate cancer risk in Asians or the hypertension link in Slovak women. A result that is common and benign in one population may carry different meaning in another, which is one reason ancestry context matters.

A direct-to-consumer report that includes one of these positions may use a different assay or different reporting conventions than a clinical-grade laboratory. If a result will inform a major decision, confirming with a clinical-grade lab is reasonable.